Jiangsu Sihuan Bioengineering Co Ltd Asset Resilience Ratio
Jiangsu Sihuan Bioengineering Co Ltd asset resilience ratio. Jiangsu Sihuan Bioengineering Co Ltd (000518) has an Asset Resilience Ratio of 0.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Jiangsu Sihuan Bioengineering Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jiangsu Sihuan Bioengineering Co Ltd (1992–2024)
Asset resilience ratio of Jiangsu Sihuan Bioengineering Co Ltd from 1992 to 2024. This chart shows how Jiangsu Sihuan Bioengineering Co Ltd's Asset Resilience Ratio has changed over time. Read Jiangsu Sihuan Bioengineering Co Ltd (000518) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Sihuan Bioengineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 000518 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥147.93K | 0.03% |
| Total Liquid Assets | CN¥147.93K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Jiangsu Sihuan Bioengineering Co Ltd maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Sihuan Bioengineering Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Sihuan Bioengineering Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Jiangsu Sihuan Bioengineering Co Ltd Asset Resilience Ratio by Year (1992–2024)
Jiangsu Sihuan Bioengineering Co Ltd asset resilience ratio by year from 1992 to 2024. The table below shows the annual Asset Resilience Ratio data for Jiangsu Sihuan Bioengineering Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.03% | CN¥171.37K ≈ $25.08K |
CN¥567.40 Million ≈ $83.03 Million |
+0.01pp |
| 2023-12-31 | 0.02% | CN¥136.22K ≈ $19.93K |
CN¥660.98 Million ≈ $96.72 Million |
0.00pp |
| 2022-12-31 | 0.02% | CN¥161.12K ≈ $23.58K |
CN¥738.08 Million ≈ $108.00 Million |
-0.01pp |
| 2021-12-31 | 0.03% | CN¥226.30K ≈ $33.11K |
CN¥799.31 Million ≈ $116.96 Million |
-0.09pp |
| 1998-12-31 | 0.12% | CN¥214.13K ≈ $31.33K |
CN¥180.33 Million ≈ $26.39 Million |
+0.06pp |
| 1997-12-31 | 0.06% | CN¥187.68K ≈ $27.46K |
CN¥299.24 Million ≈ $43.79 Million |
-0.44pp |
| 1996-12-31 | 0.51% | CN¥1.38 Million ≈ $202.45K |
CN¥273.91 Million ≈ $40.08 Million |
-2.03pp |
| 1995-12-31 | 2.54% | CN¥6.63 Million ≈ $970.41K |
CN¥261.39 Million ≈ $38.25 Million |
-0.98pp |
| 1994-12-31 | 3.52% | CN¥9.97 Million ≈ $1.46 Million |
CN¥283.19 Million ≈ $41.44 Million |
+2.97pp |
| 1993-12-31 | 0.55% | CN¥1.40 Million ≈ $204.93K |
CN¥254.61 Million ≈ $37.26 Million |
+0.45pp |
| 1992-12-31 | 0.10% | CN¥126.79K ≈ $18.55K |
CN¥126.97 Million ≈ $18.58 Million |
-- |
About Jiangsu Sihuan Bioengineering Co Ltd
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusheng and xindelusheng, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded … Read more